Interferon alfacon-1 Disease Interactions
There are 10 disease interactions with interferon alfacon-1.
- Renal dysfunction
- Autoimmune diseases
- Hepatic dysfunction
- Cardiac disease
- CNS dysfunction
- Depression
- Thyroid dysfunction
- Diabetes mellitus
- Myelosuppression
- Peripheral neuropathy
Interferon alfa (applies to interferon alfacon-1) renal dysfunction
Major Potential Hazard, High plausibility.
Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).
Interferon- alfa (applies to interferon alfacon-1) autoimmune diseases
Major Potential Hazard, Moderate plausibility. Applicable conditions: Autoimmune Disorder
Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.
Interferon-alfa (applies to interferon alfacon-1) hepatic dysfunction
Major Potential Hazard, High plausibility. Applicable conditions: Liver Disease
Hepatotoxicity, including fatal cases, has been reported in patients treated with interferon alpha. Additionally, the risk of hepatic decompensation and death is increased in patients with cirrhosis. Any patient developing liver function abnormalities during treatment should be monitored closely and treatment should be discontinued if appropriate. Interferon-alfa is contraindicated in patients with autoimmune hepatitis and decompensated liver disease.
Interferons (applies to interferon alfacon-1) cardiac disease
Major Potential Hazard, High plausibility. Applicable conditions: Ischemic Heart Disease, Arrhythmias, Congestive Heart Failure
Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.
Interferons (applies to interferon alfacon-1) CNS dysfunction
Major Potential Hazard, High plausibility. Applicable conditions: Psychosis, Parkinsonism, Seizures
Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.
Interferons (applies to interferon alfacon-1) depression
Major Potential Hazard, Moderate plausibility.
Interferons (alfa or beta) can induce depression and suicidal behavior. Suicidal attempts and suicides have been reported. Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression. Clinical monitoring of psychological status is recommended.
Interferons (applies to interferon alfacon-1) thyroid dysfunction
Major Potential Hazard, High plausibility. Applicable conditions: Hypothyroidism, Hyperthyroidism
Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons. Therapy with interferons should be administered cautiously to patients with thyroid dysfunction. If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued. Clinical monitoring of thyroid function is recommended.
Interferon alfa (applies to interferon alfacon-1) diabetes mellitus
Moderate Potential Hazard, Moderate plausibility.
Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients. Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus. Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.
Interferons (applies to interferon alfacon-1) myelosuppression
Moderate Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.
Interferons (applies to interferon alfacon-1) peripheral neuropathy
Moderate Potential Hazard, Moderate plausibility.
Paresthesia and numbness have been reported during interferon therapy. Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.
Switch to professional interaction data
Interferon alfacon-1 drug interactions
There are 215 drug interactions with interferon alfacon-1.
More about interferon alfacon-1
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: interferons
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.